|
|||||
|
|
Isolated molecular relapse in FIP1L1-PDGFRalpha hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose |
|
| Authors: | Breccia Massimo Cilloni Daniela Cannella Laura Stefanizzi Caterina Tafuri Agostino Fama Angelo Santopietro Michelina Saglio Giuseppe Alimena Giuliana |
| Affiliation: | (1) Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy;(2) Department of Clinical and Biological Sciences of the University of Turin, San Luigi Hospital, Orbassano, Turin, Italy;(3) Department of Human Biotechnology and Hematology, Via Benevento 6, 00161 Rome, Italy |
| Abstract: | Imatinib is the treatment of choice for FIP1L1-PDGFRα (F/P+) positive myeloproliferative neoplasms, but little is known about optimal dose and duration of treatment to maintain complete molecular remission once achieved. We describe a case of F/P+ patients who started imatinib and reached a molecular remission, but did relapse after 15 months of therapy for poor adherence to therapy, and re-obtained remission only with standard dose of 400 mg/day. We reviewed the literature and highlights the need of quantitative molecular procedures to modulate imatinib dose. |
| Keywords: | Imatinib Hypereosinophilic syndrome FIPL1-PDGFR-alpha Molecular remission |
| 本文献已被 PubMed SpringerLink 等数据库收录！ | |